1,041 reports of this reaction
2.5% of all RANIBIZUMAB reports
#7 most reported adverse reaction
EYE HAEMORRHAGE is the #7 most commonly reported adverse reaction for RANIBIZUMAB, manufactured by Genentech, Inc.. There are 1,041 FDA adverse event reports linking RANIBIZUMAB to EYE HAEMORRHAGE. This represents approximately 2.5% of all 41,498 adverse event reports for this drug.
Patients taking RANIBIZUMAB who experience eye haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE HAEMORRHAGE is a less commonly reported adverse event for RANIBIZUMAB, but still significant enough to appear in the safety profile.
In addition to eye haemorrhage, the following adverse reactions have been reported for RANIBIZUMAB:
The following drugs have also been linked to eye haemorrhage in FDA adverse event reports:
EYE HAEMORRHAGE has been reported as an adverse event in 1,041 FDA reports for RANIBIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE HAEMORRHAGE accounts for approximately 2.5% of all adverse event reports for RANIBIZUMAB, making it a notable side effect.
If you experience eye haemorrhage while taking RANIBIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.